Advances in radiation oncology · 2025
Particle Therapy in the Multimodal Treatment for Locally Advanced Malignancies of the Nasal Cavity and Paranasal Sinus-Single Institute Experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sheikhzadeh Fatima Frosan, Schmich Gertrud, Recknagel Niklas, Smalec Edgar, Mohamed Tasneim Abdelrahman, Soborun Vicky, Tas Kerem Tuna, Lishewski Philipp, Zink Klemens, Elsayad Khaled, Eberle Fabian, Vorwerk Hilke, Held Thomas, Stuck Boris A, Adeberg Sebastian, Gawish Ahmed
Аннотация
PURPOSE: Particle therapy with protons or carbon ions is a promising method for treating locally advanced nasal cavity and paranasal sinus carcinomas (NPSC). This study evaluates the clinical outcomes and toxicities of patients treated with carbon ion radiation therapy with a boost (CIRT-B) at our institution.
METHODS AND MATERIALS: Patients with NPSC who received combined treatment with CIRT-B and intensity modulated radiation therapy were considered. Local control (LC) and survival rates were estimated using Kaplan-Meier survival analysis and proportional hazards models.
RESULTS: Between 2016 and 2023, a total of 66 patients were included in the analysis. Of these, 53 patients (80%) received primary radiation therapy as their first-line treatment, while 13 patients (20%) underwent salvage reirradiation for recurrent disease. The median total dose administered in the upfront radiation therapy group was 74 Gy (range, 70-78 Gy relative biological effectiveness), whereas the median total dose in the salvage radiation therapy group was 45 Gy (range, 39-51 Gy relative biological effectiveness). The median duration of LC was 21 months in both the upfront and salvage groups. The overall median LC across all patients was 14 months. The 2-year LC rate was 73% for the upfront radiation therapy group and 52% for the salvage radiation therapy group, with a statistically significant difference (P = .038). In terms of early toxicities, there were no grade 4 adverse events reported.
CONCLUSIONS: CIRT-B combined with photon radiation therapy is an effective and safe treatment for advanced NPSC in both primary and salvage settings.
METHODS AND MATERIALS: Patients with NPSC who received combined treatment with CIRT-B and intensity modulated radiation therapy were considered. Local control (LC) and survival rates were estimated using Kaplan-Meier survival analysis and proportional hazards models.
RESULTS: Between 2016 and 2023, a total of 66 patients were included in the analysis. Of these, 53 patients (80%) received primary radiation therapy as their first-line treatment, while 13 patients (20%) underwent salvage reirradiation for recurrent disease. The median total dose administered in the upfront radiation therapy group was 74 Gy (range, 70-78 Gy relative biological effectiveness), whereas the median total dose in the salvage radiation therapy group was 45 Gy (range, 39-51 Gy relative biological effectiveness). The median duration of LC was 21 months in both the upfront and salvage groups. The overall median LC across all patients was 14 months. The 2-year LC rate was 73% for the upfront radiation therapy group and 52% for the salvage radiation therapy group, with a statistically significant difference (P = .038). In terms of early toxicities, there were no grade 4 adverse events reported.
CONCLUSIONS: CIRT-B combined with photon radiation therapy is an effective and safe treatment for advanced NPSC in both primary and salvage settings.